Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for advanced prostate cancer: palbociclib trial shows promise

NCT ID NCT02905318

First seen Mar 11, 2026 · Last updated May 21, 2026 · Updated 10 times

Summary

This study tests a drug called palbociclib in 19 men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if the drug can shrink tumors or slow the disease, while also monitoring side effects. Researchers will look for markers to predict which patients benefit most.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Allan Blair Cancer Centre

    Regina, Saskatchewan, S4T 7T1, Canada

  • CHUM-Centre Hospitalier de l'Universite de Montreal

    Montreal, Quebec, H2X 3E4, Canada

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, L8V 5C2, Canada

  • London Regional Cancer Program

    London, Ontario, N6A 5W9, Canada

  • Odette Cancer Centre

    Toronto, Ontario, M4N 3M5, Canada

  • QEII Health Sciences Centre

    Halifax, Nova Scotia, B3H 1V7, Canada

  • University Health Network

    Toronto, Ontario, M5G 2M9, Canada

Conditions

Explore the condition pages connected to this study.